INVESTOR RELATIONS

Investor relations

PRESS RELEASES

Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available...
2023-03-24 08:00 Lipum AB – Year-end report 2022 Regulatory
Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the...
Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety...
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming...
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2023. In accordance with the decision at the Annual...
Lipum AB has published the interim report for period July-September 2022. Below is a short summary, a complete report (only in Swedish) is available on...
Lipum AB (publ) announces that the Phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. To date, a...
The Board of Directors of Lipum resolved on September 22, 2022, subject to the approval by the General Meeting, on the Directed Share Issue of 2,601,732...
The EGM resolved to approve the Board of Directors’ previous resolution on September 22, 2022 on a directed share issue of 2,601,732 shares, whereby...
The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The...

INVESTOR RELATIONS

Investor relations